Given the potential value of JMJD6 in cancer treatment, researchers have accordingly designed an inhibitor, SKLB325, based on the crystal structure of the jmjC domain of JMJD6, which was demonstrated to possess remarkable antitumor effects in ovarian cancer.33 This evidence concerns the gene JMJD6 and ovarian cancer.